233 related articles for article (PubMed ID: 31794273)
1. Pharmacodynamics, clinical findings and approval status of current and emerging tyrosine-kinase inhibitors for pancreatic neuroendocrine tumors.
Fazio N; Cella CA; Del Re M; Laffi A; Rubino M; Zagami P; Spada F
Expert Opin Drug Metab Toxicol; 2019 Dec; 15(12):993-1004. PubMed ID: 31794273
[No Abstract] [Full Text] [Related]
2. Targeting Focal Adhesion Kinase and Resistance to mTOR Inhibition in Pancreatic Neuroendocrine Tumors.
François RA; Maeng K; Nawab A; Kaye FJ; Hochwald SN; Zajac-Kaye M
J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 25971297
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and pharmacodynamics of sunitinib for the treatment of advanced pancreatic neuroendocrine tumors.
Bisht S; Feldmann G; Brossart P
Expert Opin Drug Metab Toxicol; 2013 Jun; 9(6):777-88. PubMed ID: 23590356
[TBL] [Abstract][Full Text] [Related]
4. Autophagy Inhibition Improves Sunitinib Efficacy in Pancreatic Neuroendocrine Tumors via a Lysosome-dependent Mechanism.
Wiedmer T; Blank A; Pantasis S; Normand L; Bill R; Krebs P; Tschan MP; Marinoni I; Perren A
Mol Cancer Ther; 2017 Nov; 16(11):2502-2515. PubMed ID: 28729403
[TBL] [Abstract][Full Text] [Related]
5. Sunitinib in pancreatic neuroendocrine tumors.
Raymond E; Hammel P; Dreyer C; Maatescu C; Hentic O; Ruszniewski P; Faivre S
Target Oncol; 2012 Jun; 7(2):117-25. PubMed ID: 22661319
[TBL] [Abstract][Full Text] [Related]
6. Systemic Therapies for Metastatic Pancreatic Neuroendocrine Tumors.
Hauser H; Gerson DS; Reidy-Lagunes D; Raj N
Curr Treat Options Oncol; 2019 Nov; 20(12):87. PubMed ID: 31776785
[TBL] [Abstract][Full Text] [Related]
7. The Role of Cytotoxic Chemotherapy in Well-Differentiated Gastroenteropancreatic and Lung Neuroendocrine Tumors.
Cives M; Pelle' E; Quaresmini D; Mandriani B; Tucci M; Silvestris F
Curr Treat Options Oncol; 2019 Jul; 20(9):72. PubMed ID: 31346813
[TBL] [Abstract][Full Text] [Related]
8. Tyrosine Kinase Inhibitors and Immunotherapy Updates in Neuroendocrine Neoplasms.
Mosalem O; Sonbol MB; Halfdanarson TR; Starr JS
Best Pract Res Clin Endocrinol Metab; 2023 Sep; 37(5):101796. PubMed ID: 37414652
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic-based targeted therapies for well-differentiated pancreatic neuroendocrine tumors: recent advances and future perspectives.
Marini F; Giusti F; Brandi ML
Expert Rev Endocrinol Metab; 2021 Nov; 16(6):295-307. PubMed ID: 34554891
[TBL] [Abstract][Full Text] [Related]
10. Biological targeted therapies in patients with advanced enteropancreatic neuroendocrine carcinomas.
Fazio N; Cinieri S; Lorizzo K; Squadroni M; Orlando L; Spada F; Maiello E; Bodei L; Paganelli G; Delle Fave G; de Braud F
Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S87-94. PubMed ID: 21129617
[TBL] [Abstract][Full Text] [Related]
11. Systemic treatment of neuroendocrine tumors with hepatic metastases.
Demirkan BH; Eriksson B
Turk J Gastroenterol; 2012; 23(5):427-37. PubMed ID: 23161287
[TBL] [Abstract][Full Text] [Related]
12. Targeting Angiogenesis in Pancreatic Neuroendocrine Tumors: Resistance Mechanisms.
Pozas J; San Román M; Alonso-Gordoa T; Pozas M; Caracuel L; Carrato A; Molina-Cerrillo J
Int J Mol Sci; 2019 Oct; 20(19):. PubMed ID: 31597249
[TBL] [Abstract][Full Text] [Related]
13. Updated Efficacy and Safety Outcomes for Patients with Well-Differentiated Pancreatic Neuroendocrine Tumors Treated with Sunitinib.
Fazio N; Kulke M; Rosbrook B; Fernandez K; Raymond E
Target Oncol; 2021 Jan; 16(1):27-35. PubMed ID: 33411058
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of sunitinib in Japanese patients with progressive, advanced/metastatic, well-differentiated, unresectable pancreatic neuroendocrine tumors: final analyses from a Phase II study.
Ito T; Tori M; Hashigaki S; Kimura N; Sato K; Ohki E; Sawaki A; Okusaka T
Jpn J Clin Oncol; 2019 Apr; 49(4):354-360. PubMed ID: 30834940
[TBL] [Abstract][Full Text] [Related]
15. A Phase II Study of BEZ235 in Patients with Everolimus-resistant, Advanced Pancreatic Neuroendocrine Tumours.
Fazio N; Buzzoni R; Baudin E; Antonuzzo L; Hubner RA; Lahner H; DE Herder WW; Raderer M; Teulé A; Capdevila J; Libutti SK; Kulke MH; Shah M; Dey D; Turri S; Aimone P; Massacesi C; Verslype C
Anticancer Res; 2016 Feb; 36(2):713-9. PubMed ID: 26851029
[TBL] [Abstract][Full Text] [Related]
16. Dose and schedule modification are required for long-term continuation of sunitinib in Japanese patients with advanced pancreatic neuroendocrine tumors.
Lee L; Ito T; Igarashi H; Miki M; Fujimori N; Kawabe K; Jensen RT; Ogawa Y
Cancer Chemother Pharmacol; 2018 Jan; 81(1):163-169. PubMed ID: 29164297
[TBL] [Abstract][Full Text] [Related]
17. Medical Management of Pancreatic Neuroendocrine Tumors: Current and Future Therapy.
Chan JA; Kulke MH
Surg Oncol Clin N Am; 2016 Apr; 25(2):423-37. PubMed ID: 27013373
[TBL] [Abstract][Full Text] [Related]
18. Systemic therapies in patients with advanced well-differentiated pancreatic neuroendocrine tumors (PanNETs): When cytoreduction is the aim. A critical review with meta-analysis.
Pozzari M; Maisonneuve P; Spada F; Berruti A; Amoroso V; Cella CA; Laffi A; Pellicori S; Bertani E; Fazio N
Cancer Treat Rev; 2018 Dec; 71():39-46. PubMed ID: 30352319
[TBL] [Abstract][Full Text] [Related]
19. Systemic Therapies for Advanced Pancreatic Neuroendocrine Tumors.
Raj N; Reidy-Lagunes D
Hematol Oncol Clin North Am; 2016 Feb; 30(1):119-33. PubMed ID: 26614372
[TBL] [Abstract][Full Text] [Related]
20. Sunitinib for advanced pancreatic neuroendocrine tumors.
Hubner RA; Valle JW
Expert Rev Anticancer Ther; 2011 Dec; 11(12):1817-27. PubMed ID: 22117148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
